Post-approval drug research and surveillance had become an established part of clinical research. Non-interventional studies which are conducted once a drug has entered the market contribute significantly to the knowledge of drug effectiveness and safety in actual clinical practice. In contrast to randomised clinical trials, those studies are subject to a different set of regulatory and quality standards which are guided by the principle of non-intervention.

At ICRC-WEYER, we believe that well-conducted non-interventional research can yield valuable insights that reach beyond the constraints of clinical trials. Based on our longstanding experience in post-marketing surveillance, we have developed processes that are fully compliant with GEP/GPP, STROBE as well as national guidelines and will satisfy your high expectations concerning scientific validity.

Due to our broad experience, we are able to offer a portfolio that encompasses all areas of post-marketing, non-interventional research. Our expertise ranges from longitudinal cohort studies (including health outcome research) to post-authorisation pharmacovigilance across various therapeutic areas.

 »back to overview«

»Site selection & Patient recruitment«